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Abstract: To explain a bimodal pattern of hazard of relapse among early stage breast cancer patients identified in multiple 
databases, we proposed that late relapses result from steady stochastic progressions from single dormant malignant cells to 
avascular micrometastases and then on to growing deposits. However in order to explain early relapses, we had to postu-
late that something happens at about the time of surgery to provoke sudden exits from dormant phases to active growth 
and then to detection. Most relapses in breast cancer are in the early category. Recent data from Forget et al. suggest an 
unexpected mechanism. They retrospectively studied results from 327 consecutive breast cancer patients comparing vari-
ous perioperative analgesics and anesthetics in one Belgian hospital and one surgeon. Patients were treated with mastec-
tomy and conventional adjuvant therapy. Relapse hazard updated Sept 2011 are presented. A common Non-Steroidal 
Anti-Inflammatory Drug (NSAID) analgesic used in surgery produced far superior disease-free survival in the first 5 years 
after surgery. The expected prominent early relapse events in months 9-18 are reduced 5-fold. If this observation holds up 
to further scrutiny, it could mean that the simple use of this safe, inexpensive and effective anti-inflammatory agent at 
surgery might eliminate early relapses. Transient systemic inflammation accompanying surgery could facilitate angio-
genesis of dormant micrometastases, proliferation of dormant single cells, and seeding of circulating cancer stem cells 
(perhaps in part released from bone marrow) resulting in early relapse and could have been effectively blocked by the pe-
rioperative anti-inflammatory agent.  
Keywords: Breast cancer, early relapse, late relapse, angiogenesis, inflammation, surgery, analgesic, perioperative, metastases, 
bleeding, NSAID, dormancy. 
INTRODUCTION 
Historical Overview 
The history and philosophy of science describes progress not 
simply in steady incremental steps but with rare and wel-
come sudden leaps forward. Karl Popper described the hy-
pothetico-deductive process of observation and experimenta-
tion as “normal science” [1] whereas Thomas Kuhn de-
scribed the occasional leap forward as “revolutionary sci-
ence” and coined the expression “paradigm shift” to describe 
this phenomenon [2]. Normal science demands a method but 
revolutionary science demands an open mind. The recent 
history of the search for the cure for breast cancer can be 
described in this way.  
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Health, BLDG I, Rm 1311, 665 Huntington, Ave, Boston, MA 02115, USA; 
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From about 200 AD until the early 19thC, breast cancer 
was treated according to the traditions of the Galenic doc-
trine that declared breast cancer as a systemic disorder result-
ing from an imbalance of the natural “humours” with excess 
of the putative black bile. Relative to his time Galen (131-
203AD) was a true scientist however this was a purely meta-
physical construct that led to barbaric therapeutic interven-
tions aimed at restoring the balance of the “humours” [3]. 
Vesalius (1514–1564) was one of the first to vigorously op-
pose Galen’s doctrines. Yet, the first scientific revolution in 
the history of breast cancer was the description by Virchow 
(1821-1902) of the cellular nature of cancer and its propen-
sity to spread along the lymphatic system to be arrested in 
the axillary lymph nodes [4]. This mechanistic concept in-
formed the evolution of the radical mastectomy.  
William Halsted (1852-1922) operated at a time when the 
triumph of mechanistic principles was at its peak when the 
common man had begun enjoying the fruits of the Industrial 
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Revolution. His surgical expertise was remarkable, and for 
the first time, breast cancer seemed curable with local recur-
rence rates of only 10% at 3 years, very low compared to the 
other series at that time. Unfortunately, only about a quarter 
of patients treated by Halsted survived 10 years [5]. Thus 
even when the tumor seemed to have been completely ‘re-
moved with its roots’, the patients still developed distant 
metastases and succumbed with little evidence of “cure” if 
patients were followed up for as long as 25 years [6]. From 
the popularization of the classical radical mastectomy at the 
very end of the 19thC until about 1975, almost all patients 
with breast cancer, of a technically operable stage, were 
treated with modifications of the radical mastectomy.  
The Biological Revolution of the Late 20thC. 
Prompted by the failures of radical operations to cure pa-
tients with breast cancer, Bernard Fisher proposed a revolu-
tionary hypothesis that rejected the mechanistic model of the 
past replacing it with a biological model which challenged 
and refuted every prediction from the time of Virchow [7]. 
He postulated that cancer spreads via the blood stream 
bypassing the lymphatic channels and that this can occur 
even before the lump is first detectable; the rate of growth 
and the rate of spread being determined by the nature of the 
malignant focus at its inception.  
There were two therapeutic consequences of this concep-
tual revolution: 
(A)   The extent of local treatment by surgery and radio-
therapy might control the disease on the chest wall 
but have no effect on survival, the horse (cancer) hav-
ing bolted before the stable door (radical surgery) was 
slammed shut. 
(B)   If the outcome of treatment was pre-determined by 
the extent of microscopic subclinical metastases pre-
sent at the time of diagnosis, then the only chance of 
cure would be with adjuvant systemic therapy i.e., 
drugs targeting these putative sites of disease, even 
for patients apparently only with localized tumors. 
As regards the extent of local treatment, many trials have 
tested less versus more surgery with or without post-
operative radiotherapy [7,8]. The extent of surgery doesn’t 
appear to have significant impact on survival. The second 
prediction following the conceptual revolution spearheaded 
by Fisher, has been spectacularly corroborated by the success 
of the trials of adjuvant systemic therapy that have been mir-
rored by the fall in breast cancer mortality in many parts of 
the world since the mid-1980s [9,10]. 
Progress has now slowed down and is now best described 
in small incremental steps that begin to suggest an exhaus-
tion of the contemporary paradigm [11, 12]. Unfortunately 
revolutionary thinking cannot be conjured on demand; the 
zeitgeist has to be right. We believe that the time is indeed 
right for the rebuilding of a conceptual model of breast can-
cer resulting from the identification of outlying observations 
that are incapable of explanation according to the Fisherian 
thinking in its present form. It is our task to develop a bold 
set of conjectures that together have greater explanatory 
power while at the same time accounting for the undoubted 
successes of the last 40 years.  
Toward a New Understanding of the Natural History of 
the Disease 
Among the most striking inconsistencies between the 
“Fisherian” model and clinical observations, is the pattern of 
hazard rates for local and distant recurrences after surgery 
for clinically localized disease. Instead of these demonstrat-
ing a shape that would be consistent with a stochastic pattern 
of transition from sub-clinical micro-metastases at different 
stages of progression and different rates of cellular prolifera-
tion, we witness a double peak, the first a steep and narrow 
based peak at about one or two years after surgery and a sec-
ond lower and wider based curve reaching its plateau at 
about five or six years. [See Figs 1 and 2]. These observa-
tions, repeated in almost every data set examined by 
smoothed hazard rate plots, cannot be explained by a linear 
dynamic implicit in the current conceptual model of breast 
cancer [13-17]. 
If the facts don’t fit the model then the model is wrong, 
not the observations. Or in the words of Nassim Nicholas 
Taleb, “The black swan is an outlier, as it lays outside the 
realm of regular expectations….it carries an extreme impact 
and in spite of its outlier status, human nature makes us con-
coct explanations for its occurrence after the fact, making it 
explainable and predictable” [18]. 
Using non-linear (chaos theory) models, an adequate ex-
planation can be found for the “black swans” that include the 
biphasic relapse pattern but at the same time can account for 
the undoubted successes of the contemporary paradigm. Al-
though the number of metastases that are seeded by the pri-
mary tumor would be, at least as a working hypothesis, line-
arly related to the tumor size and biological aggressiveness, 
we suggest that the clinical appearance of metastases is often 
triggered or accelerated only after the primary tumor has 
been perturbed or removed. One has to assume that the ma-
jority of metastases at the time of diagnosis are dormant 
rather than actively growing. Within the “dormant” metasta-
ses, we can conceive of single quiescent isolated tumor cells 
and, moreover, others where there is some type of balance 
between cell growth and cell death. The latter may be partly 
determined by factors that inhibit angiogenesis without 
which a clump of cancer cells cannot grow to more than 10
6
or10
7 cells in number and other factors that inhibit epithelial 
proliferation or encourage apoptosis. Immune related factors 
may also be involved. If stimulating factors are increased or 
inhibiting factors are reduced, the dormant condition can no 
longer be maintained [19-21]. 
It is well documented in animal models and humans that 
removal of the primary tumor can reduce the inhibition of 
angiogenesis and it is recognized that following surgery, 
there is a surge in cytokine production that promotes angio-
genesis and growth factors aiding wound healing [15,22,23]. 
Thus it is not surprising that tumor angiogenesis and prolif-
eration may be provoked by the surgery involved in the at-
tempt to control primary cancer. Thus a likely trigger for 
‘kick-starting’ the growth of dormant metastases could be 
the act of surgery itself. In support of this thesis is the obser-
vation that a wound response gene expression signature can 
predict breast cancer survival [24]. Reduction of Breast Cancer Relapses with Perioperative NSAID  Current Medicinal Chemistry, 2013, Vol. 20, No. 33    4165
Fig. (1). Hazard of relapse for premenopausal patients treated atIstituto Nazionale Tumori in Milan, Italy. Hazard is the number of events that 
occur in a time interval divided by the number of patients who enter that time as event free. Patients were treated by mastectomy well before 
the routine use of adjuvant therapy. The time interval in all hazard figures used here is 3 months. Average and standard deviations are indi-
cated as diamonds and bars. The curve was obtained by a kernel-like smoothing procedure. 
Fig. (2). Same as fig. 1 except that these are postmenopausal patients. 
After surgery for breast cancer, the first peak in the inci-
dence of secondary disease occurs at about 1-2 years irre-
spective of whether the tumor was at stage I or stage III [25]. 
It is only the height of the peak that changes with stage, the 
later the stage at presentation the higher is the peak, but the 
timing of the signal remains the same. These phenomena 
suggest a nonlinear dynamic model for breast cancer, which, 
like all chaotic systems, is determined by initial conditions 
around the time of diagnosis [26]. 
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Therapeutic Consequences 
The therapeutic consequences of the new model are self-
evident. Assuming that the primary surgery (mastectomy or 
lumpectomy) removes all macroscopic evidence of disease, 
we can then visualize two families of subclinical residual 
foci, either in the tumor bed, or nesting in distant organs. 
One group would comprise organelle like structures existing 
in a relatively unstable state of dynamic equilibrium, perhaps 
awaiting a kick-start following the surgical onslaught to a 
phase of active progression; and the other consisting of small 
clusters of dormant cells destined to become apparent at any 
time between one and 25 years after surgery and relatively 
unresponsive to the initial systemic response to the surgical 
trauma. It is possible that one therapeutic option if timed 
correctly might favorably impact on both families of sub-
clinical foci but perhaps we need to consider different thera-
peutic interventions for each of the postulated residual foci 
of disease.  
This then might comprise a complex schedule of a pre or 
peri-operative biological inhibition of the response to surgery 
over a short period of time followed by a long-term drug 
schedule over many years that could include, for example, 
endocrine agents for the hormone receptor positive group of 
diseases [27] or “personalized” systemic therapies for the 
hormone receptor negative group [28]. The peri-operative 
therapy, which is non-specific for the tumor’s biological 
characteristics, could impact prominently on tumors display-
ing high rates of early relapse [29].  
Bimodal Relapse Pattern Details 
As noted, our analysis of data from the Milan National 
Cancer Institute found an unexpected bimodal pattern of 
relapse hazard among 1173 early stage breast cancer patients 
treated by mastectomy. Fig. 1 shows Milan data for 
premenopausal patients and Fig. 2 shows postmenopausal 
patients in relapse hazard format. 
There is an early peak of recurrence risk during the first 
three years of follow-up, a nadir at 50 months and a broad 
second peak extending from 60 months to over 15 years. 
Fifty to eighty percent of relapses, the proportion increasing 
with primary tumor size, reside within the first peak. Under 
closer examination, the first peak consists of two distinct 
groups centered at 10 months and 30 months that are well 
distinguishable in premenopausal patients but occur for 
postmenopausal patients as well. This pattern was not ex-
plainable by accepted theories.  
Similar patterns have now been identified in 20 inde-
pendent databases from US, Europe and Asia. One of these 
databases is shown in Fig 3 in disease free survival format. It 
may be compared to Milan data shown in the same format in 
Fig. 4. This effect is apparently not restricted to breast cancer 
Fig. (3). These are independent data for mastectomy treated patients in disease free survival format as modified from Fisher et al. Cancer 
1984 [37]. Patients are grouped by axillary lymph nodes invasion, with axillary lymph node tumor-free (N-) patients in the uppermost curve 
and patients with 10 or more invaded lymph nodes (N+) in the lower curve. The magnitude of the early relapse component may be visual-
ized. For N- patients, after surgery alone 80% of patients are long lasting disease-free with half the relapses early and half late. For the poor 
prognosis patients (N+ with 10 or more involved lymph nodes), surgery alone is quite ineffective. Most of relapses (90%) are early and sup-
port the label of “poor prognosis”. These data are visually and quantitatively very similar to the Milan data shown in fig. 4. Poor prognosis 
appears to have less impact on late relapses. 
Months post mastectomy
Relapse-free survival for patients treated only with surgery. Grouped by nodal count.  
From top, nodes = 0, 1-3, 4-6, 7-12, >12. Bimodal pattern may be seen.
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as we have noted case reports or similar recurrence dynamics 
among patients who are resected for primary control of pros-
tate, lung, and pancreatic cancers, as well as osteosarcoma 
and melanoma [30-36]. 
Fig. (4). Milan data for patients treated with mastectomy are pre-
sented in the more conventional format as disease free survival. The 
percentage disease free starts at 100% and rapidly drops until ap-
proximately 4 years where there seems to be a short plateau. Re-
lapses start to happen again at about 5 years and slowly continue 
thereafter tapering off gradually at about 15 years. The plateau at 4 
years corresponds to the end of the early relapses seen in figs. 1 and 
2. Modified from Bonadonna et al. NEJM 1995 [38]. 
Using Computer Simulation to Analyze Bimodal Relapse 
Pattern 
Based on computer simulation, to explain the 10 month 
peak we postulated that induction of angiogenesis at the time 
of surgery provoked sudden exits from dormant avascular 
phases to active growth and then to detection. That mode is 
quite sharp and most often seen among premenopausal pa-
tients with axillary lymph node involvement (N+). We sug-
gested the remainder of relapses within the first 40 or so 
months to be surgery-induced growth of previously dormant 
single malignant cells. We proposed that the broad late peak 
relapses result from steady stochastic progressions from sin-
gle dormant malignant cells to avascular micro-metastases 
and then on to growing deposits with no apparent synchroni-
zation to the time of surgery. 
We are certainly not the first to notice that removing 
breast tumors can sometimes accelerate disease and that this 
increases with tumor size. In fact, it was apparently known 
by Celsus (30BC – 38AD) and Galen. Remarkably, surgeons 
2000 years ago were able to remove breast tumors and many 
patients survived the surgery. Aulus Cornelius Celsus wrote: 
“First there is the cacoethes, then carcinoma without ulcera-
tion, then the fungating ulcer. None of these can be removed 
but the cacoethes: the rest are irritated by every method of 
cure. The more violent the operations the more angry they 
grow. Some use caustics, some burning iron, others remove 
the growth with the scalpel. After excision, even though a 
cicatrix is formed, it recurs, bringing with it the cause of 
death, whereas at the same time, most people, by using no 
violent methods to attempt the extirpation of the disease but 
only applying mild medications to soothe it, protract their 
lives, notwithstanding the disorder, to an extreme old age.’’ 
This is of course relative to the life expectancy in those 
times. Galen wrote: “We have often cured this disease in the 
early stages, but after it has grown to a noticeable size no one 
has cured it with surgery”[3]. 
Computer simulations of the two early relapse modes are 
shown in Fig. 5. Using these data and analyses, we have 
been able to help explain a wide variety of previously un-
connected breast cancer observations. These include the high 
effectiveness of adjuvant chemotherapy seen in premeno-
pausal node positive women, why mammographic screening 
is more effective for women age 50-59 than for women age 
40-49, and why there is racial disparity in outcome.  
The proposed model was further supported by the fact 
that in patients given adjuvant chemotherapy targeting pro-
liferating cells first year (angiogenesis switching-related) 
recurrences and third year (single cell wake up-related) re-
currences were remarkably reduced. Indeed, additional data 
from Milan for patients treated with CMF adjuvant chemo-
therapy (Fig. 6) provided evidence that the recurrence risk 
pattern of patients receiving adjuvant chemotherapy displays 
a single initial peak at 18-20 months and a late peak at about 
60 months.
Most Important Finding – Early Relapses are the Result 
of Something that Happens at Surgery 
The most important finding of this early work is that 
something happens at or about the time of surgery to accel-
erate or induce metastatic activity that results in early re-
lapses. These early relapses comprise over half of all re-
lapses. Surgery-induced angiogenesis of dormant avascular 
micrometastases and surgery-induced activity of single ma-
lignant cells are implicated. Late relapses are apparently not 
accelerated by surgery but the shallow peak at 5 years occurs 
as a result of shedding from primary ceasing after primary 
removal. We have been vigilantly looking for new data with 
which we can learn more about surgery-induced tumor activ-
ity and that perhaps will also lead to improved outcomes. As 
we describe here, there has been an important development. 
MATERIALS AND METHODS 
Forget et al. data 
In June 2010, Forget et al. reported data from a retrospec-
tive disease free survival study of 327 consecutive patients 
treated in one Belgian hospital. Patients were compared ac-
cording to the perioperative analgesics administered (sufen-
tanil, clonidine, ketorolac and ketamine), following the pref-
erences of the two anesthesiologists in charge [40]. As stated 
in the initial report, the sample size was limited by availabil-
ity of medical records and to maintain oncologic treatment 
homogeneity. 
Approval of the Ethical Committee of St-Luc Hospital 
was provided by the CEBH of the Université Catholique de 
Louvain (Brussels, Belgium), Chairperson Prof. Dr. J.M. 
Maloteaux. Investigators were unable to obtain consent from 
Bonadonna, Valagussa et al. NEJM 1995
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Fig. (5). Computer simulations of early relapse events. Hazard of relapse for early events centered at 10 months and at 30 months post-
surgery as proposed by computer simulation are shown. Simulations included effects of mastectomy and were based on Milan data shown in 
figs. 1 and 2. The 10 month and 30 month events may be distinguished in fig. 1 and are less clear but present in fig. 2. 
the patients for this retrospective study and the need for writ-
ten informed consent from participants was waived, as ac-
cepted by the CEBH. 
Fig. (6). The result of adjuvant CMF chemotherapy. The two early 
peaks in the untreated population coalesce into a single peak in this 
treated population at about 20 months. Apparently CMF chemo-
therapy acts to produce most extensive reduction in relapse hazard 
in the 1
st and 3
rd year [39]. 
Patients with previous ipsilateral surgery for breast can-
cer were excluded. Indications for mastectomy with axillary 
clearance were defined according to international recom-
mendations and guidelines [41,42]. These indications were 
discussed every week by the multidisciplinary board of the 
breast clinic and regularly updated  and adjusted with new 
international recommendations and relevant literature. All 
mastectomies were performed by one surgeon and jointly 
followed by the surgeon and one oncologist. Chemotherapy, 
radiotherapy and endocrine therapy were performed accord-
ing to the international expert consensus (9
th and 10
th St-
Gallen consensus) [43-46]. During the first two postopera-
tive years, medical consultation occurred each three months, 
then every 6 months during three additional years and once a 
year thereafter.  
Follow-up in that initial report was average 27.3 months 
with range 13-44 months. Patients who received anti-
inflammatory drugs were compared with those who had not 
and their hazard of recurrence was analyzed and compared. 
The type and the dosages of intraoperative analgesics 
used were, for sufentanil from 0 to 0.5  g.kg-1, for clonidine 
from 0 to 6  g.kg-1 (preincisional), for ketamine from 0 to 
0.5 mg.kg-1 (preincisional). Ketorolac, when administered, 
was used as follows: 20 mg preincisional in patients under 
60 kg, and 30 mg in patients over 60 kg.  
RESULTS 
Perioperative administration of the Non-Steroidal Anti-
Inflammatory Drug (NSAID) ketorolac, a common surgical 
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anti-inflammatory analgesic, was associated with signifi-
cantly superior disease-free survival in the first few years 
after surgery. The expected prominent early relapse risk peak 
is all but absent in the 2010 ketorolac data (Fig. 7). The few 
events in the ketorolac group show a small bump in the first 
10 months and then slowly rising until the 4
th year when fol-
low-up of this series ends. After 24 months the ketorolac 
group hazard rate pattern is indistinguishable from the corre-
sponding pattern for the no-ketorolac group. The updated 
analysis presented in Fig. 8 shows that the benefit appears in 
the 9-18 month hazards and is of magnitude 4 – 6 fold, con-
sistent with the early report. Specifically in that 9 month 
period there are 3 relapses in the ketorolac group compared 
to 15 in the no-ketorolac patients. 
Fig. (7). Forget et al. [40] data from Universite catholique de Lou-
vain in Brussels, Belgium. Relapse hazard is shown for mastectomy 
patients given ketorolac or not. Data are smoothed as indicated for 
fig. 1. 
Even with the insight of simulations, it is sometimes im-
possible to determine with certainty what happened to each 
of the various relapse modes in a particular report. However 
in this case it appears that perisurgical ketorolac is associated 
with a dramatic reduction of the recurrences that, according 
to the proposed model, are related to surgery-induced metas-
tatic activity. If this observation holds up to further scrutiny, 
it could mean that the simple use of this safe and effective 
anti-inflammatory agent at the time of surgery might elimi-
nate most early relapses.  
DISCUSSION 
We knew that some intervention starting before surgery 
would be needed to prevent surgery-induced tumor activity 
but what could explain the Forget et al. data? Published 
along with the original Forget et al. study, an outline of a 
number of possible effects of surgery and anesthesia on can-
cer growth was presented by Gottschalk et al. [47]. These 
include stress, immunosuppression, pain, transfusion, in-
flammation, hypothermia, and a few others. In view of the 
extensive literature discussing connections and correlations 
between cancer growth and inflammation, our interest was 
drawn toward inflammation as possibly a key metastasis 
producing process.  
Fig. (8). Forget et al. data were updated September 2011 and shown 
in hazard form but not smoothed as in fig. 7. Patient data are pre-
sented in the table. Patients included in this figure were less than 80 
years of age, tumor less than 9 cm diameter and disease free sur-
vival greater than 2 months. It can be seen that relapses in months 9 
-18 accounted for the major difference between ketorolac and non-
ketorolac patients.
Inflammation is the body’s response to tissue insult. 
When tissue is damaged, either by physical trauma or by 
pathogen, a complex cascade of events is triggered [48]. 
Numerous inflammatory cells and complexes collaborate to 
attack the invading pathogen, clear debris, reconstitute the 
extracellular matrix and assist in the proliferation and trans-
fer of healthy cells to the target site. The inflammatory re-
sponse is the essential and inevitable part of the repair proc-
ess and a natural defense reaction to trauma. The severity, 
timing, and local character of any particular inflammatory 
response depends on the cause, location and site of the area 
affected, and host’s condition [49,50]. The inflammatory 
response can be intensified by mast cells which release his-
tamine, which then markedly increases the permeability of 
adjacent capillaries.  
Balkwill et al. write that if genetic damage is the “match 
that lights the fire” of cancer, then inflammation is the “fuel 
that feeds the flames” and that inflammation affects both the 
survival and proliferation of already initiated cancer cells 
[51]. Inflammation is a significant component of the tumor 
microenvironment. 
Inflammatory oncotaxis, a term used to describe tumor 
growth at a site of inflammation, has long been occasionally 
seen in persons with known or occult cancer and who have 
local trauma [52]. A clinical observation published in 1914 
Months 0 6 12 18 24 30 36 42 48
Patients at risk 316 302 283 266 260 252 223 183 150
Keto group 175 168 162 157 155 151 140 115 99
No-Keto group 141 134 121 109 105 101 83 68 51
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when it was more common for persons to walk around with 
known cancer stated: “The localization of secondary tumors 
at points of injury has been so often remarked upon that it is 
unnecessary to cite specific instances. The cause for the phe-
nomenon is unknown.” [53]. As another example, El Saghir 
et al. published a case report for a smoker with unresectable 
non-small cell lung cancer who had minor head trauma and a 
7 cm diameter tumor grew there in 30 days [54]. We have 
studied and commented on this case in some detail [55]. 
Martins-Green et al. studied an avian system in which a 
virus is the carcinogenic agent [56]. When newly hatched 
chicks are given injections of Rous sarcoma virus, a tumor 
develops only at the site of injection unless a wound is made 
a distance away from the primary tumor where a tumor de-
velops at the site of wounding. They found that when in-
flammation was inhibited, tumors were also inhibited; when 
inflammation could not be stopped, tumors developed as 
before.  
Transient inflammation after surgery to remove a primary 
cancer can be both local and systemic [57]. In a colon cancer 
study, Pascual et al. measured the proinflammatory cytokine 
interleukin-6 (IL-6) in serum prior to surgery and in perito-
neal fluid during surgery to establish baseline IL-6, and 
again at 4, 12, 24 and 48 hours and at 4 days after surgery to 
determine a temporal trend. They found levels of IL-6 in 
serum at approximately 1/300 of the concentrations seen in 
peritoneal fluid. Extrapolating their data, it would seem that 
levels in serum would gradually return to baseline in a week 
or so.  
There are data associating primary surgery and transient 
inflammation for breast cancer from Chow et al. [58] and 
from Perez-Rivas et al. [59]. 
Chow et al. were studying the effect of clarithromycin on 
acute systemic inflammation after mastectomy in 54 patients. 
They measured IL-6, C - reactive protein (CRP), and tumor 
necrosis factor-alpha (TNF-alpha) in peripheral blood daily 
from the day before surgery to 3 days afterwards. These 
markers comprise an inflammation panel that is found useful 
in renal disease [60]. In both intervention and control groups 
Chow et al. found no particular change in TNF-alpha but 50 
– 60% increase in both CRP and IL-6 for 2 or 3 days after 
surgery and seem to be heading back to normal by the last 
measurement. Also of note, leukocytes increased 25-30% 
and platelets decreased 10% with the same temporal pattern 
as seen for IL-6 and CRP. 
Perez-Rivas et al. focused on the differential impact of 
breast surgery on the serum profiles of early breast cancer 
patients and healthy women. Samples were collected prior to 
and 24 hours following breast surgery. They found that sur-
gery increased the concentration of several proteins (Colony 
Stimulating Factor (CSF1), THSB2, IL-6, IL-7, IL-16, Hu-
man Epidermal Growth Factor Receptor 2 (HER2), Fas 
Ligand (FasL) and Vascular Endothelial Growth Factor B 
(VEGF-B)) in the overall population that include angiogene-
sis promoters and markers of inflammation. They report high 
velocity of change in IL-16 and VEGF-A after surgery for 
invasive disease. They suggest IL-16 is involved in escape 
from dormancy. 
There are a Number of Possible Mechanisms for a Post-
Surgical Inflammatory Reaction Effect on Tumor 
Growth 
Fig. 9 shows a schematic description of what we suspect 
to be some of the mechanisms how transient systemic in-
flammation governs metastatic relapse from early breast can-
cer.  
There are a number of reports that inflammation can spur 
angiogenesis and tumor growth [49,51,61-63]. This could 
activate growth of dormant single cells or avascular micro-
metastases resulting in early relapses. In particular, decreas-
ing the inflammatory response to the surgical maneuver 
could restrict the angiogenesis switch. A few hypothetical 
mechanisms can be put forward, including the following.  
At steady state conditions in adult mammals, most endo-
thelial cells are quiescent and are believed to contribute to 
organ homeostasis and tumor dormancy [64]. However, in 
response to inflammation the upregulation and release of 
factors stimulating endothelial cells to proliferate could also 
induce endothelial cells to secrete specific cytokines that 
reciprocally support the regeneration of normal and malig-
nant stem cells. The metastatic process is believed to be sup-
ported by tumor stem cells, which are able to reproduce the 
cancer progeny. Tumor stem cells, as normal stem cells, re-
quire a supporting “niche”, i.e., a subset of tissue cells and 
extracellular substrates defining a specialized microenviron-
ment that is able to modulate the stem cell function (quies-
cence or proliferation). The occurrence of a metastatic “vas-
cular niche” where endothelial cells play a main role and 
where an angiogenesis dependent dormancy could result 
from the cross-talk between tumor cells and endothelial cells 
(perhaps by regulation of the Notch signaling) has been sug-
gested [65]. If cancer stem cells need to interact with a vas-
cular niche to express their potential, it is reasonable that the 
latter, under an angiogenic spike by the surgical approach to 
primary tumor, may appreciably contribute to dormancy in-
terruption [66]. If so, reducing inflammation could result in 
impairment of the dormant foci wake up process.  
Additionally, circulating tumor cells could modify their 
phenotype secondary to an inflammatory stimulus. When not 
only analysed for their number, but also for their expression 
profile linked to activation and ability to adhere, a prerequi-
site for metastasis formation, circulating tumor cells can 
modify the expression of nanog, a sign of stem cell proper-
ties which enables the cells to self renew and grow. Other 
factors, like EpCAM, her2/neu, and the adhesion molecule 
vimentin are other well-known risk factors of proliferation 
possibly influenced by inflammation [67,68]. 
Tissue lesions induce mobilization of bone marrow de-
rived cells that are capable of responding to chemo-attractant 
signals from various organs, where they undergo a homing 
process and where they release several chemokines [69]. 
This phenomenon is prominent during neovascularization of 
wounded tissues via direct or paracrine activity inducing 
capillary formation. A common basis of the above-
mentioned processes is cell trafficking [69]. Indeed, while 
the intravascular dissemination of normal stem cells is essen-
tially passive, mobilization from their usual niche and hom-
ing in a given tissue is regulated by specific signals. Reduction of Breast Cancer Relapses with Perioperative NSAID  Current Medicinal Chemistry, 2013, Vol. 20, No. 33    4171
Fig. (9). Symbolic description of proposed explanations for Forget et al. data. Early relapses are assumed to be related, at least in part, to the 
inflammatory process due to primary tumor surgical removal, directly or indirectly eliciting peritumoral endothelial cell and single cell prolif-
eration. A few possible mechanisms are explained. A) Angiogenic factors, like VEGF and bFGF, are directly released by degranulated plate-
lets or even produced via IL-6; B) Bone marrow derived CXCR-4 positive cells, acting both on tumor foci and on the inflammatory process, 
are mobilized by SDF-1 directly released or even produced via COX-2. Perioperative ketorolac would restrict both endocrine and cellular 
pathways, thus impairing the metastatic process. CTC refers to circulating tumor cells.
Hematopoietic stem cells, for example, express the 
chemokine receptor CXCR4 and selectively respond to SDF-
1. The SDF-1/CXCR4 axis is a main regulator of the nor-
mal cell trafficking underlying the tissue homeostasis. It is 
also involved in tumor cell trafficking as CXCR4 overex-
pression is known in more than 20 human tumor types, in-
cluding ovarian, prostate, esophageal, melanoma, neuroblas-
toma, and renal cell carcinoma [70]. It is, therefore, reason-
able to hypothesize that NSAIDs may interfere with SDF1 
levels via the pathway COX-2  PGE  SDF-1, thus re-
sulting in impairment of processes underlying metastasis 
development.  
Even if an NSAID class effect is plausible, a specific ef-
fect of ketorolac remains possible. As already stated, 
whereas all NSAIDs act against the growth of tumors, they 
are probably not equivalent for this antitumoral effect [40]. 
Alternative targets, such as the tumor-associated NADH 
oxydase (tNOX), are possibly involved in this anticancer 
effect. The existence of tNOX explains the fact that some 
cancer cell lines lacking COX-2 respond to certain NSAIDs 
but not to others, suggestive of additional COX-2 independ-
ent antitumor activities [71]. 
Another possible explanation for the lack of surgery-
induced angiogenesis when ketorolac is used involves in-
flammation induced platelet degranulation and that platelets 
are known to sequester angiogenesis regulating proteins in-
cluding VEGF [72]. This is especially interesting in view of 
Chow et al. findings that platelets decrease by about 10% in 
the few days post-surgery. There is also a report that 
NSAIDs are antiangiogenic and another report that transcript 
of stem cell marker CD133 that is correlated with poor prog-
nosis in a number of solid tumors was lower in patients 
treated preoperatively with NSAIDs [73,74].  
It is well established that many cancer patients have cir-
culating tumor cells [75-77] and there are cells released as a 
result of surgery [78]. Camara et al. data show a surge in 
circulating epithelial cells after primary breast cancer sur-
gery, but intriguingly, that surge occurs 3-7 days after sur-
gery. Such a delayed increase in what may be circulating 
tumor cells after breast cancer surgery was also reported by 
Daskalakis et al. [79]. This phenomenon recalls the surge of 
CD34+ progenitor cells 3-5 days after tissue damage (e.g., 
myocardial infarction) [80]. Also it has been recently re-
ported in an animal model, where mice with subcutaneous 
implantation of Lewis lung carcinoma were subjected to an 
operative injury, that surgery induced the release of cytoki-
nes/chemokines and mobilized bone marrow–derived cells 
(BMDC) [81]. These mobilized cells were then recruited into 
tumor tissue with concomitant enhancement of angiogenesis, 
thereby accelerating tumor growth. Furthermore, blocking 
recruitment of bone marrow stem cells by disrupting 
SDF/CXCR signals completely negated the accelerated tu-
mor growth. Many questions arise. Are these surged cells 
reported by Camara [78] shed or spilled into circulation dur-
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ing surgery and if so why are they delayed by a few days? Or 
perhaps are these cells released from the bone marrow as 
part of the programmed wound healing process? Is this a 
connection to Dvorak’s comment that cancer is” wound heal-
ing gone awry” [82]? What exactly controls this effect? Can 
a perioperative NSAID stop this process?  
 It further suggests that tumors may share physiological 
mechanisms with normal tissues and, moreover, that inhibit-
ing the inflammatory process might reduce late metastases as 
well as can be seen in a recent report of daily use of aspirin 
[83]. Interestingly, the benefit of daily aspirin does not ap-
pear until after 2 years of use. This would be consistent with 
the possibility that late relapses are the result of late inflam-
mation driven events that induce single cell growth and that 
result in relapses approximately 30 months hence. If late 
relapses were the result of surgery-induced angiogenesis, we 
would expect to see a benefit of daily aspirin at 10 or so 
months after starting. 
Blood flow in capillaries is only 0.05cm/sec [84] which 
would make leaky capillary venules a very efficient way for 
circulating tumor cells to enter tissue. It may be that what we 
previously called dormant single cells induced into metas-
tatic growth were at least in some cases residing not at the 
site of eventual relapse. Rather, circulating tumor cells or 
BMDC released into circulation by a host response to sur-
gery in an inflammatory environment extravasate, resulting 
months later in a metastatic tumor. Circulating tumor cells 
are a reality. Surgical induction of inflammation is universal. 
Capillary leakage is enhanced by inflammation. It is thereby 
logical to expect that an effective perisurgical anti-
inflammatory strategy may affect surgery-induced and pos-
sibly angiogenesis-mediated cancer spread. 
The metastatic process is highly inefficient. A clonal ma-
lignant cell injected into the circulation has approximately 
0.0001 probability to result in a growing metastatic site [85]. 
Inflammation bypasses the need for extravasation through an 
intact vessel wall and also provides growth factors to the 
microenvironment. We estimate the metastatic seeding proc-
ess is amplified 100 fold during the few days or weeks after 
primary surgery. 
Are the missing early relapses never to happen or are 
they merely postponed to become late relapses? Whatever 
their source and shedding timing, cancer cells in circulation 
may have half-life of a few days or less. Unless injected into 
more hospitable surroundings such as tissue, these cells will 
likely harmlessly die off. These data and our analysis suggest 
that at least for some patients the early relapses apparently 
avoided in the Forget et al. data do not show up later. 
Lastly, the reduced recurrence risk for patients receiving 
perioperative NSAID may be attributed, at least in part, to 
the reduced usage of opioids for pain management with ke-
torolac [86,87]. It cannot be excluded that all the above men-
tioned mechanisms could act together resulting in relapses 
within the subsequent few years. 
TNBC and Early Relapses – Possibly an Ideal Group for 
Testing Perioperative Ketorolac 
We now turn our attention to methods of testing this new 
hypothesis. Animal studies would be very important, how-
ever in view of the analyses and data presented we think this 
should be tested prospectively in a clinical trial. The next 
question that arises is what patient group would be a good 
candidate for a trial. Most breast cancer clinical trials, at 
least in the US, focus on distinct patient subgroups based on 
recurrence risk levels. The triple negative subgroup attracted 
our attention for several reasons [29]. Lacking markers for 
HER2, Estrogen or Progesterone receptors that strongly sug-
gest that there is benefit of targeted therapy, triple negative 
breast cancer (TNBC) is looked upon by clinicians as a “bad 
tumor” with high recurrence rate in spite of adjuvant chemo-
therapy. That pessimistic viewpoint seems justified since 
TNBC has 12% incidence but accounts for approximately 
20% of mortality in breast cancer.  
We had access to a triple negative breast cancer data base 
from Milan that we analyzed with our hazard methods. The 
relapse hazard (Fig. 10) looks remarkably similar to the no-
ketorolac group in the Forget et al. study shown in Fig. 7.
Triple negative breast cancer therefore appears to be the 
ideal study group with which to test benefit of perioperative 
ketorolac in a clinical trial.  
The incidence of TNBC is 12% in US population (as 
mentioned), 25% among African Americans, and 25% to 
35% among patients from India and Korea [88-90]. (There 
may be other as yet unexamined groups also with high inci-
dence of TNBC.) Locations with relatively high incidence of 
TNBC would be ideal places to conduct a clinical trial in 
order to make it easier to show an improvement in early re-
lapse. 
As noted by Wallace et al, the racial disparity in breast 
cancer outcome is due primarily to deaths within the first 
few years after diagnosis providing an additional motivation 
to test at the earliest opportunity what we report here [91]. 
That would be consistent with the information just noted.
Concerns About Bleeding Complications 
One of the issues related to the perioperative use of ke-
torolac has been concern about bleeding complications. 
What is the evidence, if any, regarding the occurrence of 
increased blood loss and its clinical significance after a sin-
gle or limited number of doses of ketorolac when adminis-
tered during the perioperative period? 
This topic has been recently addressed in an editorial by 
White, Raeder and Kehlet, accompanying a meta-analysis of 
De Oliveira et al. [92,93]. In the meta-analysis, the authors 
noted that the combined effect did show a statistically sig-
nificant increase in bleeding with ketorolac compared with 
placebo. This effect was however shown only in two studies 
focusing on surgeries with "raw" surface areas (adenotonsil-
lectomy and major orthopedic surgery) and without any ad-
ditional red blood cell transfusion needed, questioning the 
clinical significance in other surgeries.  
In breast surgery, a recent retrospective study in major 
plastic breast reconstructive surgery (mammoplasty) reported 
a greater likelihood of requirement for surgical hematoma 
evacuation [94]. But, as in surgeries with "raw" surface ar-
eas, such major plastic surgeries are associated with greater 
difficulties in hemostasis than lumpectomy (often performed 
on a day-case basis) or mastectomy. Two studies in breast Reduction of Breast Cancer Relapses with Perioperative NSAID  Current Medicinal Chemistry, 2013, Vol. 20, No. 33    4173
Fig. (10). Hazard data from a Milan database for 121 TNBC patients with 10-11 years follow up. There are 50 relapse events within 5 years
of surgery. The general similarity of these hazard data to Forget et al. data for no-ketorolac patients seen in Fig. 7 leads to the suggestion that 
TNBC may be the ideal study group with which to test perioperative ketorolac. 
cancer surgery prospectively compared ketorolac with pla-
cebo. The first did not show any difference in drain output, 
but is difficult to interpret because ketorolac was adminis-
tered near the end of surgery (in place of preincisional) [95]. 
The second showed a statistically significant difference but 
no clinical implications including no need of transfusion in 
any group [96]. 
As a consequence, if the use of ketorolac has been asso-
ciated with a greater amount of blood loss in a limited num-
ber of studies and not in others, the clinical significance re-
mains unknown in breast cancer surgery. If any, it seems to 
be low since ketorolac has never been associated with greater 
transfusion need of red blood cells. Studies even tend to re-
port a better functional outcome in the postoperative period 
with ketorolac, suggesting that the clinical significance of 
this blood loss could be largely counterbalanced by the ad-
vantage of the drug [92,93]. As a consequence, the American 
Society of Anesthesiologists recommended in their latest 
guidelines that unless contraindicated, all the patients should 
receive balanced analgesia, including NSAIDs [97]. 
SUMMARY AND CONCLUSIONS 
Careful analysis of breast cancer recurrences suggests a 
paradigm where early recurrences, i.e. the majority of ad-
verse events resulting in poor prognosis, are induced by an-
giogenic switching of avascular micrometastases and single 
cell activation. Both events are triggered by primary tumor 
surgical removal.  
Results reported by Forget et al. analysis of retrospective 
data, suggesting perioperative NSAID ketorolac significantly 
reduces early relapses, may be deciphered in the light of this 
model. Indeed, post-surgical transient systemic inflammation 
might be the precipitating factor and common denominator 
for early relapses. In particular, inflammation would be im-
portant for angiogenesis induction of avascular distant mi-
crometastases.  
Several molecular processes could be involved, either as 
single mechanisms or concurrently. For example, inflamma-
tion induced upregulation and release of factors stimulating 
endothelial cells to proliferate could also induce endothelial 
cells to secrete specific cytokines that reciprocally support 
the regeneration malignant stem cells within the metastatic 
niche. Or else, as the SDF-1/CXCR4 axis is a main regulator 
of normal and tumoral cell trafficking, it is reasonable to 
hypothesize that NSAIDs may interfere with SDF1 levels via 
the pathway COX-2  PGE  SDF-1, thus resulting in im-
pairment of processes underlying metastasis development. 
Another possible explanation involves inflammation induced 
platelet degranulation, with release of angiogenesis regulat-
ing factors including VEGF, which would be countered by 
ketorolac. Lastly, tumor cells released as a result of surgery 
in the presence of transient systemic inflammation and capil-
lary permeability could also account for succeeding metas-
tatic development. 
A few points need further investigations. First, the Forget 
et al. findings need to be confirmed in randomized clinical 
trials. Such investigations are imperative not only from the 
scientific point of view but more so for their possible clinical 
consequences, resulting from the fact that breast cancer mor-
tality could be reduced by 25 to 50% at low cost and toxicity. 
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A subset of patients for a randomized clinical trial should be 
characterized by unfavorable prognostic factors resulting in 
early recurrences covering the first 2 to 3 years. We suggest 
that the best breast cancer population for such a trial may be 
triple negative breast cancer. 
In spite of the fact that breast cancer is known as a dis-
ease that runs its course in a decade or more, most of the 
relevant events resulting in recurrences apparently occur 
shortly after primary surgery. Investigations focused on 
events occurring during the first few days and weeks follow-
ing primary tumor removal are strongly warranted. 
Winquist and Boucher describe the lack of innovative 
new paths moving forward in cancer therapeutics as bleak 
with improvements often measured in months [12]. The new 
path outlined here could be a revolutionary break (“Some-
thing for nothing” rarely if ever happened in cancer therapy) 
from the past and should also be explored in other neopla-
sias. High priority should be given to test this hypothesis as 
it is implementable regardless of state of socio-economic 
development because of its low cost. We end by acknowl-
edging the seminal work of friends and mentors Bernard 
Fisher and the late Judah Folkman and we   note with regret  
the death from cancer of our esteemed colleague Isaac Gu-
kas. 
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